TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25041494
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg in 50 ml infusion
Study: 25041494
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg in 250 ml infusion
Study: 25041494
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg (50 ml and 250 ml)
Study: 18455908
Drug: rTMS (1Hz)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS (1Hz) with exposure therapy
Study: 18455908
Drug: Sham (placebo)
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (placebo) with exposure therapy
Study: 17485893
Drug: Pioglitazone hydrochloride
Normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone hydrochloride (15 mg or 30 mg)
Study: 17485893
Drug: Glibenclamide (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (1.25 mg or 2.5 mg)
Study: 15001191
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg olmesartan
Study: 15001191
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg olmesartan
Study: 15001191
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg olmesartan
Study: 15001191
Drug: olmesartan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan (all doses)
Study: 11260006
Drug: F6‐1,25(OH)2D3 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: F6‐1,25(OH)2D3 (5 microg in 0.1 g of petrolatum)
Study: 11260006
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 g of petrolatum)
Study: 11260006
Drug: F6‐1,25(OH)2D3 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: F6‐1,25(OH)2D3 (50 microg g‐1 of petrolatum) applied to all lesions
Study: 7999600
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate solution (1 mg/ml)
Study: 7999600
Drug: Calcipotriol solution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol solution (50 micrograms/ml)
Study: 31325822
Drug: Multicomponent cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent cognitive-behavioral therapy (adapted for lower socioeconomic groups or standard) + 8 weeks of nicotine patches
Study: 26111351
Drug: Prostvac-VF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostvac-VF vaccine followed by docetaxel chemotherapy (Arm A, n = 6)
Study: 26111351
Drug: Docetaxel chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy alone (Arm B, n = 2)
Study: 23424237
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily with bendroflumethiazide 1.25 mg (CB)
Study: 23424237
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily with placebo (CP)
Study: 21894078
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tramadol mixed with 20 ml of sugar syrup
Study: 31809408
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tramadol
Study: 17115390
Drug: 0.2 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 per cent glyceryl trinitrate (GTN) ointment
Study: 17115390
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (petroleum jelly)
Study: 8169417
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment for 10 days
Study: 8169417
Drug: Antimicrobial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial treatment alone
Study: 2901037
Drug: Single perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single perioperative course of adjuvant combination chemotherapy beginning within 36 hours of mastectomy
Study: 2901037
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of conventionally timed adjuvant chemotherapy starting 25 to 32 days after operation
Study: 2901037
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival differences favored the longer treatments
Study: 25302462
Drug: Intravascular low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular low-level laser therapy (LLLT)
Study: 20297611
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) 50 microg
Study: 20297611
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) 100 microg
Study: 20297611
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) 200 microg
Study: 20297611
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) (all doses)
Study: 12412840
Drug: Dronabinol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (2.5 mg)
Study: 2479252
Drug: Hydrochlorothiazide 100
Normalized name: hydrochlorothiazide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 100 mg daily
Study: 31923242
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of oral Mg++ citrate (n = 66)
Study: 31923242
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Mg++ and placebo)
Study: 22659994
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 16 mg galantamine plus 20 mg memantine
Study: 22659994
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg galantamine alone
Study: 22659994
Drug: Galantamine (as
Normalized name: benzgalantamine (as gluconate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (as part of the combination regimen or as mono treatment)
Study: 12471291
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy treatment (McConnell-based)
Study: 8120307
Drug: Influenza hemagglutinin-diphtheria
Normalized name: Bordetella pertussis filamentous hemagglutinin vaccine, inactivated / Bordetella pertussis pertactin vaccine, inactivated / Bordetella pertussis toxoid vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Infanrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza hemagglutinin-diphtheria toxoid conjugate vaccine (HA-D)
Study: 8120307
Drug: Influenza hemagglutinin-subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza hemagglutinin-subunit vaccine (HA)
Study: 2517008
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg
Study: 2571296
Drug: Reference alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference alpha 2‐agonists
Study: 31901705
Drug: COMBO450 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBO450 (450 mg of encorafenib QD + 45 mg of binimetinib BID)
Study: 31901705
Drug: ENCO300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENCO300 (300 mg of encorafenib QD)
Study: 31901705
Drug: VEM (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEM (960 mg of vemurafenib BID)
Study: 30640775
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of TXA 100 mg/1 mL
Study: 30640775
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of TXA 100 mg/1 mL in anticoagulant subgroup
Study: 30640775
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) in anticoagulant subgroup
Study: 19491837
Drug: Baclofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (3 x 20 mg) during PPI treatment
Study: 19491837
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during PPI treatment
Study: 8602379
Drug: clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 250 mg
Study: 8602379
Drug: doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 100 mg twice/day for 7 days
Study: 2813982
Drug: Ambroxol 75
Normalized name: ambroxol 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 75 mg once a day after breakfast for 30 days
Study: 1069366
Drug: i.v. pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pulse doses of 13‐nle‐m (0.05, 0.1, 0.2, and 0.4 mug/kg)
Study: 1069366
Drug: i.v. bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus injections of 0.6 mug/kg pentagastrin
Study: 1069366
Drug: i.v. infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusions of 13‐nle‐m (0.1, 0.2, and 0.4 mug/kg‐h)
Study: 1069366
Drug: i.v. pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pulse dose of 0.1 mug/kg 13‐nle‐m with concomitant atropine
Study: 29493409
Drug: Brief Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive-Behavioral Therapy (CBT)
Study: 22460459
Drug: Melatonin 2x5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2x5 mg daily
Study: 17601560
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of sustained-release morphine sulfate
Study: 17601560
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of sustained-release morphine sulfate
Study: 9521487
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g or 6 g, intravenous infusion for 30 min)
Study: 9521487
Drug: L-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (10 microM-2.5 mM, in vitro preincubation)
Study: 7543691
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin (6 g per liter of extracted liquid)
Study: 7543691
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (6 g per liter of extracted liquid)
Study: 30325178
Drug: Pegvisomant (PEGV),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (PEGV), average daily dose increased from 12.8 mg (year 1) to 18.9 mg (year 10)
Study: 26797837
Drug: Neoadjuvant radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant radiochemotherapy (50 Grays over six weeks and four cycles of mFOLFOX6 chemotherapy)
Study: 17126918
Drug: Ribosomal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribosomal immunotherapy (one tablet a day, 8 days a month for 3 months)
Study: 11313088
Drug: Antidepressants (pharmacotherapy)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (pharmacotherapy)
Study: 11313088
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (antidepressants + 16 sessions of Short Psychodynamic Supportive Psychotherapy)
Study: 9138281
Drug: 25 mg,
Normalized name: 0.25 MG, 0.5 MG Dose 3 ML Ozempic 0.68 MG/ML Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg, 100 mg or 300 mg lamivudine daily for 6 months
Study: 2908102
Drug: Cabergoline 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.3 mg
Study: 2908102
Drug: Cabergoline 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.6 mg
Study: 2908102
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg (Control)
Study: 2908102
Drug: Cabergoline 0.3-0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.3-0.6 mg (repeated administration)
Study: 2908102
Drug: Cabergoline 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.6 mg (increased dose)
Study: 2908102
Drug: Cabergoline (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (any dose)
Study: 29210921
Drug: Probiotics administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administration during late pregnancy and first 6 months of life
Study: 29210921
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration during late pregnancy and first 6 months of life
Study: 28175315
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide
Study: 28175315
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide in HIV co-infected patients on efavirenz-based ART
Study: 28175315
Drug: Moxifloxacin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin alone (single dose) after TB treatment completion
Study: 12966542
Drug: Vaccine therapy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine therapy (n = 13)
Study: 12966542
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control, n = 6)
Study: 8218760
Drug: TJ-43 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-43 (2.5 g three times daily)
Study: 25129395
Drug: Fluralaner (25-56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner (25-56 mg/kg; Bravecto™)
Study: 25129395
Drug: Spinosad (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinosad (30-60 mg/kg; Comfortis®) with amitraz collar (9%; Preventic®)
Study: 22944002
Drug: l‐dopa 'on'/DBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐dopa 'on'/DBS 'on'
Study: 22944002
Drug: l‐dopa 'on'/DBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐dopa 'on'/DBS 'off'
Study: 22944002
Drug: l‐dopa 'off'/DBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐dopa 'off'/DBS 'on'
Study: 22944002
Drug: l‐dopa 'off'/DBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐dopa 'off'/DBS 'off'
Study: 22944002
Drug: Combined effect
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined effect of DBS and l‐dopa administration
Study: 22944002
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment conditions combined
Study: 20540847
Drug: Aripiprazole (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2.5-10 mg/d)
Study: 20540847
Drug: Tiapride (25-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (25-400 mg/d)
Study: 2697693
Drug: Ayurvedic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic preparation (Aegle marmelos correa plus Bacopa monniere Linn)
Study: 2697693
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (clidinium bromide, chlordiazepoxide and isaphaghulla)
Study: 2697693
Drug: Ayurvedic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic preparation
Study: 2697693
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy and Ayurvedic therapy
Study: 2697693
Drug: Both forms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both forms of therapy (Ayurvedic and Standard)
Study: 7410127
Drug: Intravenous Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Methotrexate (25 mg every third day for 5 doses) followed by definitive radiotherapy
Study: 26936776
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate treatment for 6 weeks
Study: 25208127
Drug: Angiotensin-(1-7) infusion
Normalized name: Angiotensin (1-7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-(1-7) infusion (0.27, 0.9, and 2.7 ng/kg per min)
Study: 21822162
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 70 mg daily (35 mg × 2)
Study: 9675609
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (20 ml/day)
Study: 9675609
Drug: Soybean phosphatidylcholine
Normalized name: Soybean Phosphatidylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean phosphatidylcholine (PC) (25 g/day)
Study: 8008712
Drug: Small intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small intestinal infusion (SI) of benazepril hydrochloride (20 mg)
Study: 8008712
Drug: Colonic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colonic infusion (COLON) of benazepril hydrochloride (20 mg)
Study: 8008712
Drug: Oral bolus
Normalized name: phenylbutazone 1000 MG Oral Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bolus solution (ORAL) of benazepril hydrochloride (20 mg)
Study: 8008712
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of metabolite-to-drug AUC ratios
Study: 31233326
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n = 25)
Study: 26035087
Drug: Breathing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing therapy with instructions to raise pCO2
Study: 26035087
Drug: Breathing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing therapy with instructions to lower pCO2
Study: 21723534
Drug: Higher treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher treatment expectations
Study: 21723534
Drug: Pre-treatment OCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment OCD severity and prior treatment history
Study: 18807252
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (interactive educational meeting plus feedback on medication)
Study: 16683061
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg bupropion
Study: 16683061
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sertraline
Study: 7718029
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ascorbate supplementation (4.5 g/day)
Study: 2530713
Drug: Selective thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective thromboxane receptor antagonist
Study: 782997
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anesthesia with lidocaine
Study: 28839342
Drug: VBZ 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBZ 80 mg
Study: 28839342
Drug: VBZ 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBZ 40 mg
Study: 21511217
Drug: Adjunctive cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive cilostazol (triple group; n = 64)
Study: 21511217
Drug: High maintenance-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maintenance-dose clopidogrel (high-MD group; n = 62)
Study: 17257284
Drug: IFG-lower (5.6-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFG-lower (5.6-6.0 mmol/l)
Study: 17257284
Drug: IFG-original (6.1-6.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFG-original (6.1-6.9 mmol/l)
Study: 17257284
Drug: All-IFG (5.6-6.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-IFG (5.6-6.9 mmol/l)
Study: 17257284
Drug: Normoglycaemia (<
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycaemia (< 5.6 mmol/l)
Study: 8274782
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) cream 0.1%
Study: 8274782
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide plus retinoic acid (TARA) cream 0.1% plus 0.025%
Study: 3116836
Drug: Milk, ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk, ice milk, ice cream, frozen yogurts (without cultures)
Study: 26556618
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 µg/kg (medical patients) or 1.5 µg/kg (surgical patients) administered 10 min before turning
Study: 26556618
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 10 min before turning
Study: 20459856
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aspirin within 1.5 hours after start of thrombolysis
Study: 20459856
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (antiplatelet therapy after 24 hours)
Study: 18753120
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg daily for 48 weeks)
Study: 18753120
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg daily for 48 weeks)
Study: 18753120
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH; 2 mg for 12 weeks)
Study: 18753120
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) combined with Rosiglitazone